Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials.
Salvatore CoralloGiovanni FucàFederica MoranoMassimiliano SalatiAndrea SpallanzaniAnnunziata GloghiniChiara Costanza VolpiDesirè Viola TrupiaRiccardo LobefaroVincenzo GuariniMassimo MilioneLaura CattaneoMaria AntistaMichele PrisciandaroAlessandra RaimondiCarlo SpositoVincenzo MazzaferroFilippo G De BraudFilippo PietrantonioMaria Di BartolomeoPublished in: The oncologist (2020)
To date, no data are available on the prevalence and clinical characteristics of patients with Epstein-Barr virus (EBV)-positive metastatic gastric cancer (GC), a specific subtype of GC showing excellent outcomes after radical surgery in early-stage disease and responsiveness to immune checkpoint inhibitors (ICIs). This cohort study showed that patients with EBV-positive GC who did not receive ICIs had exceptional, long-lasting, and even complete responses to first-line chemotherapy with fluorouracil and platinum and a significantly better survival compared with EBV-negative patients. If confirmed in larger series, these results may give a strong rationale for investigating the combination of chemotherapy and ICIs to achieve durable and potentially complete response in this uncommon subtype of GC.
Keyphrases
- epstein barr virus
- diffuse large b cell lymphoma
- early stage
- end stage renal disease
- gas chromatography
- squamous cell carcinoma
- small cell lung cancer
- chronic kidney disease
- ejection fraction
- minimally invasive
- locally advanced
- clinical trial
- risk factors
- peritoneal dialysis
- patient reported outcomes
- acute coronary syndrome
- atrial fibrillation
- deep learning
- percutaneous coronary intervention
- artificial intelligence
- data analysis